



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

*In re the Application of:*

Applicant(s) : Susan E. Conroy, Heidrun Engler,  
and Daniel C. Maneval

Title : Nucleic Acid Delivery

Serial No. : 10/003,494

Filed : November 1, 2001

Docket No. : CJ-01353K

Examiner: Bronwen Loeb

Group Art Unit: 1636

TECH CENTER 1600/2900

**Transmittal of Information  
Disclosure Statement Pursuant  
to 37 C.F.R. 1.97(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:


The attached Information Disclosure Statement is submitted pursuant to 37 C.F.R. 1.97(b)(3), *i.e.* prior to the first office action on the merits.

The undersigned hereby certifies that each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the submission of this Information Disclosure Statement.

Applicants believe that no fee is associated with the submission of this Information Disclosure Statement. However, in the event the Commissioner determines that a fee is warranted by this communication, the Commissioner is hereby authorized to charge any fees deemed necessary to Deposit Account No. 50-0551.

Canji, Inc.  
3525 John Hopkins Court  
San Diego, CA 92121  
Telephone: 858-646-5955  
Facsimile: 858-452-4945

Respectfully submitted,

  
Richard B. Murphy  
Attorney for Applicant(s)  
Registration No. 35,296


Dated: August 14, 2002

**CERTIFICATE OF MAILING**

The undersigned hereby certifies that the attached correspondence is being deposited as First Class Mail with sufficient postage with the United States Postal Service in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on the date indicated below.

  
Richard B. Murphy

August 14, 2002  
August 14, 2002



PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number

10/003,494

Filing Date

11/01/2001

RECEIVED

First Named Inventor

Conroy

AUG 20

Group Art Unit

1636

TECH CENTER

1600/2900

Examiner Name

Bronwen Loeb

Total Number of Pages in This Submission

Attorney Docket Number

## ENCLOSURES (check all that apply)

- Fee Transmittal Form
  - Fee Attached
- Amendment / Reply
  - After Final
  - Affidavits/declaration(s)
- Extension of Time Request
- Express Abandonment Request
- Information Disclosure Statement
- Certified Copy of Priority Document(s)
- Response to Missing Parts/ Incomplete Application
  - Response to Missing Parts under 37 CFR 1.52 or 1.53

- Assignment Papers (for an Application)
- Drawing(s)
- Licensing-related Papers
- Petition
- Petition to Convert to a Provisional Application
- Power of Attorney, Revocation Change of Correspondence Address
- Terminal Disclaimer
- Request for Refund
- CD, Number of CD(s) \_\_\_\_\_

- After Allowance Communication to Group
- Appeal Communication to Board of Appeals and Interferences
- Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- Proprietary Information
- Status Letter
- Other Enclosure(s) (please identify below):

Postcard Receipt

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm  
or  
Individual name

Richard B. Murphy

Signature

08/14/2002

Date

## CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date:

8/14/02

Typed or printed name


Richard B. Murphy

Signature

Date

08/14/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Sheet 1 of 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: <b>CJ-01353</b>	SERIAL NO.: <b>10/003/494</b>
<b>INFORMATION DISCLOSURE STATEMENT FOR PATENT</b> <i>(Use several sheets if necessary)</i>				APPLICANT: <b>Conroy, et al.</b>	
				FILING DATE: <b>11/01/01</b>	GROUP: <b>1636</b>

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	<b>6,066,468</b>	<b>05/00</b>	<b>Burnham et al.</b>			<b>06/07/95</b>
AB						
AC						
AD						<b>AUG 20 2002</b>
AE						
AF						
AG						
AH						
AI						
AJ						
AK						

RECEIVED

AUG 20 2002  
TECH CENTER 1600/2900

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
						YES
FA	<b>EP 0 935 967 A2</b>	<b>10/98</b>	<b>Europe</b>			✓
FB	<b>WO 01/12231 A1</b>	<b>02/01</b>	<b>PCT</b>			
FC						
FD						
FE						

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

PA	Conroy, Susan et al. <i>In Vitro</i> Viral Vector Stability and Fluid Dynamics of an Intraperitoneal Solution for Delivery of Gene Therapy, 03/02, Proceedings of the American Association for Cancer Research, Vol. 41, p. 524
PB	Engler, Heidrun et al., Enhancement of intraperitoneal adenovirus mediated transgene expression by icodextrin in animal models, 11/02, Clinical Cancer Research, Vol. 6, No. 11, p. 516
PC	International Search Report and Notification of Transmittal of International Search Report (PCT/GB 01/04878) (8 sheets)
PD	
PE	
PF	

EXAMINER:	DATE CONSIDERED
-----------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Part of Paper No. 2